BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009;15:526-32. [PMID: 20010173 DOI: 10.1097/PPO.0b013e3181c5214b] [Cited by in Crossref: 88] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, Spyridopoulos T, Chatziioannou A, Sotirchos V, Karampelas T. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol. 2014;37:165-175. [PMID: 24263774 DOI: 10.1007/s00270-013-0777-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 7.2] [Reference Citation Analysis]
2 Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015; 7(5): 787-798 [PMID: 25914779 DOI: 10.4254/wjh.v7.i5.787] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 14.4] [Reference Citation Analysis]
3 Wang Z, Mu K, Lv Y, Zhao L, Li B, Hao Y, Wang N. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients. Ir J Med Sci. [DOI: 10.1007/s11845-021-02851-5] [Reference Citation Analysis]
4 Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O'Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012;35:980-5. [PMID: 22009576 DOI: 10.1007/s00270-011-0287-7] [Cited by in Crossref: 174] [Cited by in F6Publishing: 163] [Article Influence: 15.8] [Reference Citation Analysis]
5 Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, Barakat M, Huppert P. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. Cardiovasc Intervent Radiol 2018;41:587-93. [PMID: 29167967 DOI: 10.1007/s00270-017-1839-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
6 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015;88:20140564. [PMID: 25978585 DOI: 10.1259/bjr.20140564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
7 Gjoreski A, Popova-Jovanovska R, Eftimovska-Rogac I, Vejseli J. Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. Open Access Maced J Med Sci 2019;7:742-6. [PMID: 30962831 DOI: 10.3889/oamjms.2019.179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Lewis AL, Dreher MR, O'Byrne V, Grey D, Caine M, Dunn A, Tang Y, Hall B, Fowers KD, Johnson CG, Sharma KV, Wood BJ. DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med 2016;27:13. [PMID: 26676859 DOI: 10.1007/s10856-015-5629-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
9 Cascella T, Garanzini EM, Lanocita R, Morosi C, Riva F, Greco G, Sposito C, Mazzaferro V, Marchianò A, Spreafico C. Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. Cardiovasc Intervent Radiol 2022;45:54-61. [PMID: 34820694 DOI: 10.1007/s00270-021-02991-2] [Reference Citation Analysis]
10 Martin R, Irurzun J, Munchart J, Trofimov I, Scupchenko A, Tatum C, Narayanan G. Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. Korean J Hepatol 2011;17:51-60. [PMID: 21494078 DOI: 10.3350/kjhep.2011.17.1.51] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
11 Taguchi K, Sauer TJ, Segars WP, Frey EC, Xu J, Liapi E, Stayman JW, Hong K, Hui FK, Unberath M, Du Y. Three-dimensional regions-of-interest-based intra-operative four-dimensional soft tissue perfusion imaging using a standard x-ray system with no gantry rotation: A simulation study for a proof of concept. Med Phys 2020;47:6087-102. [PMID: 33006759 DOI: 10.1002/mp.14514] [Reference Citation Analysis]
12 Osuga K, Maeda N, Higashihara H, Hori S, Nakazawa T, Tanaka K, Nakamura M, Kishimoto K, Ono Y, Tomiyama N. Current status of embolic agents for liver tumor embolization. Int J Clin Oncol 2012;17:306-15. [PMID: 22806426 DOI: 10.1007/s10147-012-0445-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
13 Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2015;25:380-390. [PMID: 25226843 DOI: 10.1007/s00330-014-3412-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
14 Dreher MR, Sharma KV, Woods DL, Reddy G, Tang Y, Pritchard WF, Chiesa OA, Karanian JW, Esparza JA, Donahue D, Levy EB, Willis SL, Lewis AL, Wood BJ. Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol 2012;23:257-64.e4. [PMID: 22178039 DOI: 10.1016/j.jvir.2011.10.019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 6.7] [Reference Citation Analysis]
15 Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K. Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases. Clin Exp Metastasis 2017;34:51-62. [PMID: 27812769 DOI: 10.1007/s10585-016-9829-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
16 Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017;27:526-35. [PMID: 27277261 DOI: 10.1007/s00330-016-4445-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
17 Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011;34:37-49. [PMID: 21069333 DOI: 10.1007/s00270-010-0012-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 6.4] [Reference Citation Analysis]
18 Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
19 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
20 Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E, Geschwind JF. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology. 2013;266:636-648. [PMID: 23143027 DOI: 10.1148/radiol.12112316] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
21 Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 2013;36:449-59. [PMID: 22722717 DOI: 10.1007/s00270-012-0424-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
22 Abe H, Kamimura K, Terai S. Drug-eluting beads in hepatocellular carcinoma. Therap Adv Gastroenterol 2017;10:337-8. [PMID: 28246550 DOI: 10.1177/1756283X16681710] [Reference Citation Analysis]
23 Kim AY, Frantz S, Krishnan P, DeMulder D, Caridi T, Lynskey GE, Spies JB. Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. PLoS One 2017;12:e0183861. [PMID: 28863147 DOI: 10.1371/journal.pone.0183861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Han S, Zhang X, Zou L, Lu C, Zhang J, Li J, Li M. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS One. 2014;9:e102686. [PMID: 25083860 DOI: 10.1371/journal.pone.0102686] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
25 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
26 Wege H, Li J, Ittrich H. Treatment Lines in Hepatocellular Carcinoma. Visc Med 2019;35:266-72. [PMID: 31602390 DOI: 10.1159/000501749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
27 Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L. Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2015;2:399-408. [PMID: 26998220 DOI: 10.2217/hep.15.32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Loffroy R, Favelier S, Cherblanc V, Estivalet L. C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients. Quant Imaging Med Surg 2013;3:196-9. [PMID: 24040615 DOI: 10.3978/j.issn.2223-4292.2013.08.05] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
29 Lin M, Pellerin O, Bhagat N, Rao PP, Loffroy R, Ardon R, Mory B, Reyes DK, Geschwind JF. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2012;23:1629-1637. [PMID: 23177109 DOI: 10.1016/j.jvir.2012.08.028] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
30 Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, Zhou G, Zhou J, Zhang X, Ji W, Yu Z, Li T, Zhu D, Hu W, Ji J, Du H, Shi C, Guo X, Fang J, Han J, Gu W, Xie X, Sun Z, Xu H, Wu X, Hu T, Huang J, Hu H, Zheng J, Luo J, Chen Y, Yu W, Shao G. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncol Res 2020;28:249-71. [PMID: 31856933 DOI: 10.3727/096504019X15766663541105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015;15:465. [PMID: 26059447 DOI: 10.1186/s12885-015-1480-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
32 Mahnken AH. [Transarterial ablative therapy of hepatocellular carcinoma]. Radiologe 2014;54:685-93. [PMID: 25047524 DOI: 10.1007/s00117-014-2655-1] [Reference Citation Analysis]
33 Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-7. [PMID: 21911714 DOI: 10.1200/JCO.2011.37.1021] [Cited by in Crossref: 196] [Cited by in F6Publishing: 126] [Article Influence: 17.8] [Reference Citation Analysis]
34 Bains LJ, Zweifel M, Thoeny HC. Therapy response with diffusion MRI: An update. Cancer Imaging. 2012;12:395-402. [PMID: 23022595 DOI: 10.1102/1470-7330.2012.9047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
35 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
36 Sun JH, Zhou GH, Zhang YL, Nie CH, Zhou TY, Ai J, Zhu TY, Wang WL, Zheng SS. Chemoembolization of liver cancer with drug-loading microsphere 50-100μm. Oncotarget 2017;8:5392-9. [PMID: 28036272 DOI: 10.18632/oncotarget.14281] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
37 Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30:381. [PMID: 23292867 DOI: 10.1007/s12032-012-0381-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
38 Jazieh KA, Arabi M, Khankan AA. Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. Saudi J Gastroenterol 2014;20:333-41. [PMID: 25434313 DOI: 10.4103/1319-3767.145315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Muros-ortega M, Díaz-carrasco MS, Capel A, Calleja MÁ, Martínez F. Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. Int J Clin Pharm 2013;35:1105-12. [DOI: 10.1007/s11096-013-9831-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
40 Chen S, Yu W, Zhang K, Liu W, Chen C. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatol Res 2021;51:482-9. [PMID: 33462925 DOI: 10.1111/hepr.13620] [Reference Citation Analysis]
41 Malagari K, Emmanouil E, Pomoni M, Kelekis D. Chemoembolization with DC Bead™ for the treatment of hepatocellular carcinoma: an update. Hepat Oncol 2014;1:205-14. [PMID: 30190955 DOI: 10.2217/hep.13.18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
42 Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology 2013;268:420-30. [PMID: 23616631 DOI: 10.1148/radiol.13122307] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
43 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
44 Bishay VL, Maglione K, Khanna R, Lee KM, Fischman AM, Lookstein RA, Kim E. Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. J Hepatocell Carcinoma 2014;1:187-93. [PMID: 27508187 DOI: 10.2147/JHC.S71602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]